University of Leicester nets $3.6M grant for protein drug-target work; pSivida begins PhIII eye implant trial;

> The University of Leicester corralled a £2.4 million ($3.6 million) research funding grant for its work on gene expression that could lead to anti-cancer drugs using protein complexes as drug targets. Report

> pSivida ($PSDV) began a Phase III pivotal trial, the first of two, for its micro-insert designed to treat chronic, non-infectious uveitis affecting the posterior segment of the eye. Release

> Researchers at RMIT in Australia have created nanoparticles called yoctowells that allow for better encapsulation of drugs and controlled release. Story

> Oxford professor Constantin Coussios is looking into the potential of ultrasound as a drug-delivery tool, most particularly for people with vertebrae problems. Article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.